NEW YORK, Sept. 6 /PRNewswire/ -- A Special Committee of the Board of Directors of Merck & Co., Inc. today released a report by The Honorable John S. Martin, Jr. of Debevoise & Plimpton LLP (the “Martin Report”) setting forth the factual record and conclusions resulting from a 20-month independent investigation into the integrity of Merck’s senior management in the development, testing and marketing of Vioxx (rofecoxib). The Martin Report, while not endorsing every action that Merck employees took with respect to Vioxx, found that Merck’s senior management acted with integrity. The Martin Report and accompanying Appendices comprise more than 1,700 pages.
